Table 4.
Persistence | |||
---|---|---|---|
3 months | 6 months | 12 months | |
ACE | 83.6% | 75.3% | 64.5% |
ARB | 84.8% | 77.5% | 66.3% |
β-blockers | 86.3% | 80.0% | 70.4% |
Spironolactone | 76.3%* | 65.3%* | 50.7%* |
* Spironolactone versus ACE, ARB and β-blockers: p < 0.001 (Pearson's chi square test)